Nephros
NEPH
21 hedge funds and large institutions have $19.8M invested in Nephros in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
147% more capital invested
Capital invested by funds: $8.02M → $19.8M (+$11.8M)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
17% more funds holding
Funds holding: 18 → 21 (+3)
1.77% more ownership
Funds ownership: 44.01% → 45.78% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$318K |
| 2 |
TCM
Topline Capital Management
Santa Monica,
California
|
+$148K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$66.3K |
| 4 |
Renaissance Technologies
New York
|
+$29.1K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
-$65.2K |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$32.3K |
| 3 |
Morgan Stanley
New York
|
-$9.37K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.52K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$358 |
NEPH Hedge Fund Activity: Q2 2025 in Review
21 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Nephros (NEPH) for Q2 2025, worth a combined $19.8M — up 147% from $8.02M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NEPH positions and 1 closed out — a net gain of 3 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $318K. The largest seller was Elkhorn Partners, cutting an estimated $65.2K.
- 21 institutional investors held Nephros (NEPH) as of Q2 2025, up from 18 in Q1 2025.
- Funds reported $19.8M of Nephros stock for Q2 2025, up 147% quarter-over-quarter.
- 4 funds opened new Nephros positions in Q2 2025 and 1 closed out, a net change of +3 holders.
- The largest Nephros buyer in Q2 2025 was Vanguard Group, an estimated $318K added.
- The largest Nephros seller in Q2 2025 was Elkhorn Partners, an estimated $65.2K sold.
Based on aggregated 13F filings for Q2 2025.